Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours

NCT01581060 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
41
Enrollment
INDUSTRY
Sponsor class

Stopped Study terminated for business reasons

Conditions

Interventions

Sponsor

Heidelberg Pharma AG